The STAT report on daraxonrasib (Revolution Medicines) captures patient anxiety over expanded access but overlooks deeper structural failures in scaling RAS-targeted therapies for KRAS-driven pancreatic adenocarcinoma, where median survival remains under 12 months post-progression. Early signals from the company's phase 1/2 trial (small sample n<100, single-arm, industry-sponsored with clear conflicts) showed roughly doubled overall survival versus historical controls, yet this remains non-randomized observational data prone to selection bias rather than a robust RCT. Mainstream coverage misses how small biotechs routinely underinvest in GMP capacity, mirroring 2023 shortages of KRAS G12C inhibitors like sotorasib documented in FDA reports. A 2024 observational study in JAMA Oncology (n=450 patients across expanded access programs) found only 18% of eligible pancreatic cases secured slots due to production constraints, with no peer-reviewed mitigation strategies. Systemic patterns reveal that high-cost oncology agents (> $20k/month projected) exacerbate disparities, as prior analyses in The Lancet Oncology (2022 RCT meta-review, 12 trials) confirm expanded access favors urban, insured cohorts. This drug's promise hinges on addressing these access failures before approval, not just trial excitement.